SCHEMBL3272873

SCHEMBL3272873

Nc1ccc(Cl)cc1NC(=O)C=Cc1ccc2ccccc2c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 1/20 0.53
HDAC4 P56524 2/20 0.53
MEF2D Q14814 2/20 0.53
EP300 Q09472 1/20 0.53
MEN1 O00255 2/20 0.51
NPC1 O15118 2/20 0.51
RAB9A P51151 2/20 0.51
KMT2A Q03164 2/20 0.51
SMN1; SMN2 Q16637 2/20 0.51
KDM4E B2RXH2 1/20 0.51
ALDH1A1 P00352 1/20 0.51
HPGD P15428 1/20 0.51
NPSR1 Q6W5P4 1/20 0.51
CYP3A4 P08684 2/20 0.51
CYP1A2 P05177 1/20 0.51
CYP2C19 P33261 1/20 0.51
HCAR2 Q8TDS4 1/20 0.49
TRPA1 O75762 1/20 0.49
MMP1 P03956 2/20 0.48
MMP2 P08253 2/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3272868 1.00 EGFR (0.53) EGFRHDAC4MEF2DEP300MEN1
SCHEMBL3273286 0.86 MMP1 (0.59) EGFRKDM4EHCAR2TRPA1MMP1
SCHEMBL3273292 0.86 MMP1 (0.59) EGFRKDM4EHCAR2TRPA1MMP1
SCHEMBL3274042 0.84 TRPA1 (0.64) EGFRMEN1NPC1RAB9AKMT2A
SCHEMBL3274049 0.84 TRPA1 (0.64) EGFRMEN1NPC1RAB9AKMT2A
SCHEMBL3273766 0.83 EGFR (0.54) EGFRMEN1NPC1RAB9AKMT2A
SCHEMBL3273770 0.83 EGFR (0.54) EGFRMEN1NPC1RAB9AKMT2A
SCHEMBL3280717 0.82 EGFR (0.50) EGFRHDAC4MEN1NPC1RAB9A
SCHEMBL3280709 0.82 EGFR (0.50) EGFRHDAC4MEN1NPC1RAB9A
SCHEMBL3273607 0.81 RAB9A (0.49) EGFRMEN1NPC1RAB9AKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100087496-A1 NOVEL CINNAMIC AMIDE DERIVATIVES USEFUL AS ION CHANNEL MODULATORS NEUROSEARCH A/S (DK) 2010-04-08 US claimed
US-20100087496-A1 NOVEL CINNAMIC AMIDE DERIVATIVES USEFUL AS ION CHANNEL MODULATORS NEUROSEARCH A/S (DK) 2010-04-08 US disclosed
EP-2121569-A2 NOVEL CINNAMIC AMIDE DERIVATIVES USEFUL AS ION CHANNEL MODULATORS NEUROSEARCH A/S (DK) 2009-11-25 EP disclosed
WO-2008074755-A2 NOVEL CINNAMIC AMIDE DERIVATIVES USEFUL AS ION CHANNEL MODULATORS NEUROSEARCH A/S (DK) 2008-06-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100087496-A1 NOVEL CINNAMIC AMIDE DERIVATIVES USEFUL AS ION CHANNEL MODULATORS TRPV1, TRPA1, TRPM8 EGFR 2980/4885HDAC4 198/4885MEF2D 3254/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.